Complementation of Plasmodium berghei TRAP knockout parasites using human dihydrofolate reductase gene as a selectable marker

Ali Sultan, Vandana Thathy, Tania F. De Koning-Ward, Victor Nussenzweig

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Previously we have used the Plasmodium dihydrofolate reductase thymidylate synthase (DHFR-TS) selectable marker to generate Plasmodium berghei TRAP null mutant parasites. These TRAP null mutants do not glide and they showed a great reduction in their ability to infect mosquito salivary glands and the hepatocytes of the vertebrate host. Thus far, complementation of these knockout parasites was not possible due to the lack of additional selectable markers. Recently, a new selectable marker, based on the human dihydrofolate reductase (hDHFR) gene, has been developed which confers resistance to the antifolate drug WR99210. This drug has been found to be highly active against pyrimethamine-sensitive and -resistant strains of P. berghei. In this study, we have used the hDHFR gene as a second selectable marker for the complementation of P. berghei TRAP null mutant parasites. Restoration of the TRAP null mutant parasites to the wild-type phenotype was achieved in this study via autonomously replicating episomes bearing a wild-type copy of the TRAP gene. This is the first report of complementation of a mutant phenotype in malaria parasites.

Original languageEnglish
Pages (from-to)151-156
Number of pages6
JournalMolecular and Biochemical Parasitology
Volume113
Issue number1
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Plasmodium berghei
Tetrahydrofolate Dehydrogenase
Parasites
Genes
Folic Acid Antagonists
Phenotype
Pyrimethamine
Plasmodium
Salivary Glands
Culicidae
Pharmaceutical Preparations
Malaria
Vertebrates
Hepatocytes
Plasmids

Keywords

  • Genetic complementation
  • Human dihydrofolate reductase (hDHFR)
  • Plasmodium berghei
  • Thrombospondin-related anonymous protein (TRAP)

ASJC Scopus subject areas

  • Molecular Biology
  • Parasitology

Cite this

Complementation of Plasmodium berghei TRAP knockout parasites using human dihydrofolate reductase gene as a selectable marker. / Sultan, Ali; Thathy, Vandana; De Koning-Ward, Tania F.; Nussenzweig, Victor.

In: Molecular and Biochemical Parasitology, Vol. 113, No. 1, 2001, p. 151-156.

Research output: Contribution to journalArticle

@article{570543fb38b042e1b7388de229b72025,
title = "Complementation of Plasmodium berghei TRAP knockout parasites using human dihydrofolate reductase gene as a selectable marker",
abstract = "Previously we have used the Plasmodium dihydrofolate reductase thymidylate synthase (DHFR-TS) selectable marker to generate Plasmodium berghei TRAP null mutant parasites. These TRAP null mutants do not glide and they showed a great reduction in their ability to infect mosquito salivary glands and the hepatocytes of the vertebrate host. Thus far, complementation of these knockout parasites was not possible due to the lack of additional selectable markers. Recently, a new selectable marker, based on the human dihydrofolate reductase (hDHFR) gene, has been developed which confers resistance to the antifolate drug WR99210. This drug has been found to be highly active against pyrimethamine-sensitive and -resistant strains of P. berghei. In this study, we have used the hDHFR gene as a second selectable marker for the complementation of P. berghei TRAP null mutant parasites. Restoration of the TRAP null mutant parasites to the wild-type phenotype was achieved in this study via autonomously replicating episomes bearing a wild-type copy of the TRAP gene. This is the first report of complementation of a mutant phenotype in malaria parasites.",
keywords = "Genetic complementation, Human dihydrofolate reductase (hDHFR), Plasmodium berghei, Thrombospondin-related anonymous protein (TRAP)",
author = "Ali Sultan and Vandana Thathy and {De Koning-Ward}, {Tania F.} and Victor Nussenzweig",
year = "2001",
doi = "10.1016/S0166-6851(01)00209-2",
language = "English",
volume = "113",
pages = "151--156",
journal = "Molecular and Biochemical Parasitology",
issn = "0166-6851",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Complementation of Plasmodium berghei TRAP knockout parasites using human dihydrofolate reductase gene as a selectable marker

AU - Sultan, Ali

AU - Thathy, Vandana

AU - De Koning-Ward, Tania F.

AU - Nussenzweig, Victor

PY - 2001

Y1 - 2001

N2 - Previously we have used the Plasmodium dihydrofolate reductase thymidylate synthase (DHFR-TS) selectable marker to generate Plasmodium berghei TRAP null mutant parasites. These TRAP null mutants do not glide and they showed a great reduction in their ability to infect mosquito salivary glands and the hepatocytes of the vertebrate host. Thus far, complementation of these knockout parasites was not possible due to the lack of additional selectable markers. Recently, a new selectable marker, based on the human dihydrofolate reductase (hDHFR) gene, has been developed which confers resistance to the antifolate drug WR99210. This drug has been found to be highly active against pyrimethamine-sensitive and -resistant strains of P. berghei. In this study, we have used the hDHFR gene as a second selectable marker for the complementation of P. berghei TRAP null mutant parasites. Restoration of the TRAP null mutant parasites to the wild-type phenotype was achieved in this study via autonomously replicating episomes bearing a wild-type copy of the TRAP gene. This is the first report of complementation of a mutant phenotype in malaria parasites.

AB - Previously we have used the Plasmodium dihydrofolate reductase thymidylate synthase (DHFR-TS) selectable marker to generate Plasmodium berghei TRAP null mutant parasites. These TRAP null mutants do not glide and they showed a great reduction in their ability to infect mosquito salivary glands and the hepatocytes of the vertebrate host. Thus far, complementation of these knockout parasites was not possible due to the lack of additional selectable markers. Recently, a new selectable marker, based on the human dihydrofolate reductase (hDHFR) gene, has been developed which confers resistance to the antifolate drug WR99210. This drug has been found to be highly active against pyrimethamine-sensitive and -resistant strains of P. berghei. In this study, we have used the hDHFR gene as a second selectable marker for the complementation of P. berghei TRAP null mutant parasites. Restoration of the TRAP null mutant parasites to the wild-type phenotype was achieved in this study via autonomously replicating episomes bearing a wild-type copy of the TRAP gene. This is the first report of complementation of a mutant phenotype in malaria parasites.

KW - Genetic complementation

KW - Human dihydrofolate reductase (hDHFR)

KW - Plasmodium berghei

KW - Thrombospondin-related anonymous protein (TRAP)

UR - http://www.scopus.com/inward/record.url?scp=0035092413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035092413&partnerID=8YFLogxK

U2 - 10.1016/S0166-6851(01)00209-2

DO - 10.1016/S0166-6851(01)00209-2

M3 - Article

VL - 113

SP - 151

EP - 156

JO - Molecular and Biochemical Parasitology

JF - Molecular and Biochemical Parasitology

SN - 0166-6851

IS - 1

ER -